$OCUL News

Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win

Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Ocular Therapeutix, Inc. (OCUL) Presents at American Academy of Ophthalmology Retina Subspeciality Day - Slideshow

UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. (OCUL) Presents at Euretina 2026 - Slideshow

Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws Scrutiny

OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD

3 Reasons to Avoid OCUL and 1 Stock to Buy Instead

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success

HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

Ocular Therapeutix Announces Completion Of Pre-NDA Meeting With FDA For Investigational Product Candidate AXPAXLI For Treatment Of Wet Age-Related Macular Degeneration

Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences